Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
Open Access
- 27 October 2021
- journal article
- research article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 6 (1) , 1-7
Abstract
This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL). ORIENT-4 is a multicenter, single-arm, phase 2 clinical trial (NCT03228836). Patients with r/r ENKTL who failed to at least one asparaginase-based regimen were enrolled to receive sintilimab 200 mg intravenously every 3 weeks for up to 24 months. The primary endpoint was the objective response rate (ORR) based on Lugano 2014 criteria. Twenty-eight patients with r/r ENKTL were enrolled from August 31, 2017 to February 7, 2018. Twenty-one patients (75.0%, 95% CI: 55.1–89.3%) achieved an objective response. With a median follow-up of 30.4 months, the median overall survival (OS) was not reached. The 24-month OS rate was 78.6% (95% CI, 58.4–89.8%). Most treatment-related adverse events (TRAEs) were grade 1–2 (71.4%), and the most common TRAE was decreased lymphocyte count (42.9%). Serious adverse events (SAEs) occurred in 7 (25.0%) patients, and no patient died of adverse events. Sintilimab is effective and well tolerated in patients with r/r ENKTL and could be a novel therapeutic approach for the control of ENKTL in patients.Keywords
This publication has 32 references indexed in Scilit:
- A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysisThe Lancet Oncology, 2016
- Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphomaBritish Journal of Haematology, 2016
- PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In VitroPLOS ONE, 2015
- Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphomaAnnals of Oncology, 2015
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term SurvivorsJournal of Clinical Oncology, 2013
- Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphomaInvestigational New Drugs, 2012
- Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group StudyJournal of Clinical Oncology, 2011
- Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 studyBlood, 2011
- Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancerAnnals of Oncology, 2011
- Phase I study of dexamethasone, methotrexate, ifosfamide, l ‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemiaCancer Science, 2008